Achillion Pharma CEO talks up sale amid Hep C trials

Achillion Pharmaceuticals CEO Michael Kishbauch told Bloomberg that his drug development group has entered serious talks with potential partners and parties interested in buying his company, with the firm's board of directors preferring the latter. "We're prepared to be patient and pick the best deal," he told the news service. The firm's lead drug ACH-1625 is in mid-stage development for hepatitis C virus. Article

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.